$334 Million is the total value of Integral Health Asset Management, LLC's 60 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 223.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LHCG | Buy | LHC GROUP INC | $21,790,000 | +210.8% | 125,000 | +150.0% | 6.52% | +111.3% |
| BMY | Buy | BRISTOL-MYERS SQUIBB CO | $11,760,000 | +20.6% | 200,000 | +14.3% | 3.52% | -18.0% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $11,016,000 | +138.4% | 175,000 | +59.1% | 3.30% | +62.1% |
| CRL | New | CHARLES RIV LABS INTL INC | $9,589,000 | – | 55,000 | +100.0% | 2.87% | – |
| ABC | New | AMERISOURCEBERGEN CORP | $9,069,000 | – | 90,000 | +100.0% | 2.72% | – |
| NVRO | Buy | NEVRO CORP | $8,960,000 | +124.1% | 75,000 | +87.5% | 2.68% | +52.4% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $8,580,000 | +144.5% | 110,000 | +83.3% | 2.57% | +66.2% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $8,108,000 | +66.1% | 195,000 | +14.7% | 2.43% | +12.9% |
| CYTK | Buy | CYTOKINETICS INC | $8,014,000 | +112.4% | 340,000 | +6.2% | 2.40% | +44.4% |
| HUM | Buy | HUMANA INC | $7,755,000 | +393.9% | 20,000 | +300.0% | 2.32% | +235.5% |
| SGEN | New | SEATTLE GENETICS INC | $7,646,000 | – | 45,000 | +100.0% | 2.29% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $7,484,000 | – | 12,000 | +100.0% | 2.24% | – |
| MOH | New | MOLINA HEALTHCARE INC | $7,119,000 | – | 40,000 | +100.0% | 2.13% | – |
| NUVA | New | NUVASIVE INC | $6,958,000 | – | 125,000 | +100.0% | 2.08% | – |
| DXCM | New | DEXCOM INC | $6,081,000 | – | 15,000 | +100.0% | 1.82% | – |
| UHS | New | UNIVERSAL HLTH SVCS INCcl b | $6,038,000 | – | 65,000 | +100.0% | 1.81% | – |
| AMGN | New | AMGEN INC | $5,897,000 | – | 25,000 | +100.0% | 1.77% | – |
| LLY | New | LILLY ELI & CO | $5,746,000 | – | 35,000 | +100.0% | 1.72% | – |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $5,709,000 | +85.7% | 50,000 | +25.0% | 1.71% | +26.3% |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $4,991,000 | – | 150,000 | +100.0% | 1.50% | – |
| ABT | Buy | ABBOTT LABS | $4,572,000 | +28.8% | 50,000 | +11.1% | 1.37% | -12.5% |
| HZNP | New | HORIZON THERAPEUTICS PUB LTD | $4,446,000 | – | 80,000 | +100.0% | 1.33% | – |
| BAX | New | BAXTER INTL INC | $4,305,000 | – | 50,000 | +100.0% | 1.29% | – |
| ZBH | New | ZIMMER BIOMET HOLDINGS INC | $4,178,000 | – | 35,000 | +100.0% | 1.25% | – |
| NVST | New | ENVISTA HOLDINGS CORPORATION | $3,691,000 | – | 175,000 | +100.0% | 1.10% | – |
| HALO | Buy | HALOZYME THERAPEUTICS INC | $3,619,000 | +302.1% | 135,000 | +170.0% | 1.08% | +173.7% |
| GOSS | New | GOSSAMER BIO INC | $3,510,000 | – | 270,000 | +100.0% | 1.05% | – |
| PODD | New | INSULET CORP | $3,497,000 | – | 18,000 | +100.0% | 1.05% | – |
| AKBA | Buy | AKEBIA THERAPEUTICS INC | $3,395,000 | +123.9% | 250,000 | +25.0% | 1.02% | +52.2% |
| New | MODERNA INCput | $3,211,000 | – | 50,000 | +100.0% | 0.96% | – | |
| DNLI | Buy | DENALI THERAPEUTICS INC | $3,143,000 | +99.4% | 130,000 | +44.4% | 0.94% | +35.6% |
| CHNG | New | CHANGE HEALTHCARE INC | $2,800,000 | – | 250,000 | +100.0% | 0.84% | – |
| New | INTRA CELLULAR THERAPIES INCcall | $2,567,000 | – | 100,000 | +100.0% | 0.77% | – | |
| ABBV | New | ABBVIE INC | $2,455,000 | – | 25,000 | +100.0% | 0.74% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $2,440,000 | – | 20,000 | +100.0% | 0.73% | – |
| ZGNX | New | ZOGENIX INC | $2,431,000 | – | 90,000 | +100.0% | 0.73% | – |
| AMRN | New | AMARIN CORP PLCspons adr new | $2,422,000 | – | 350,000 | +100.0% | 0.72% | – |
| MGNX | New | MACROGENICS INC | $1,954,000 | – | 70,000 | +100.0% | 0.58% | – |
| BGNE | New | BEIGENE LTDsponsored adr | $1,884,000 | – | 10,000 | +100.0% | 0.56% | – |
| PTCT | New | PTC THERAPEUTICS INC | $1,522,000 | – | 30,000 | +100.0% | 0.46% | – |
| GNMK | New | GENMARK DIAGNOSTICS INC | $1,471,000 | – | 100,000 | +100.0% | 0.44% | – |
| INCY | New | INCYTE CORP | $1,040,000 | – | 10,000 | +100.0% | 0.31% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 15 | Q3 2023 | 4.7% |
| SAGE THERAPEUTICS INC | 15 | Q2 2023 | 5.0% |
| BIOMARIN PHARMACEUTICAL INC | 15 | Q2 2023 | 4.1% |
| ENVISTA HOLDINGS CORPORATION | 14 | Q3 2023 | 4.0% |
| AKERO THERAPEUTICS INC | 14 | Q3 2023 | 1.5% |
| REVVITY INC | 13 | Q3 2023 | 4.2% |
| BLUEPRINT MEDICINES CORP | 13 | Q3 2023 | 3.3% |
| PTC THERAPEUTICS INC | 13 | Q2 2023 | 1.7% |
| ELEVANCE HEALTH INC | 12 | Q3 2023 | 6.7% |
| NEVRO CORP | 12 | Q4 2022 | 4.5% |
View Integral Health Asset Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-12 |
| 13F-HR | 2022-02-02 |
| 13F-HR | 2021-11-12 |
View Integral Health Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.